Bristol-Myers Highlights Blood Cancer Programs at ASH 2026
Bristol-Myers said its CELMoD programs are advancing across multiple myeloma and lymphoma. The body mentions Phase 3 readouts for ZENBEXUS but is truncated.
Bristol-Myers said its CELMoD programs are advancing across multiple myeloma and lymphoma. The body mentions Phase 3 readouts for ZENBEXUS but is truncated.